- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Gastrointestinal tuberculosis.
Displaying page 1 of 2.
EudraCT Number: 2011-004268-31 | Sponsor Protocol Number: 20110118 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: Adalimumab (Humira) in the treatment of chronic pouchitis | |||||||||||||
Medical condition: Chronic pouchitis after proctocolectomy and reconstruction with a J-pouch and with ulcerative colitis as primary diagnosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002018-29 | Sponsor Protocol Number: A3921165 | Start Date*: 2020-12-09 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS | |||||||||||||
Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012566-32 | Sponsor Protocol Number: 20090061 | Start Date*: 2010-02-05 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) LV (Completed) PL (Completed) HU (Completed) BG (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020063-21 | Sponsor Protocol Number: ILUVIT1 | Start Date*: 2010-06-15 | |||||||||||
Sponsor Name:Charité-Universitätsmedizin | |||||||||||||
Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis” | |||||||||||||
Medical condition: Urticarial vasculitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005251-13 | Sponsor Protocol Number: 20110166 | Start Date*: 2012-06-05 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Moderate to severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) DE (Prematurely Ended) DK (Prematurely Ended) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) NL (Completed) AT (Completed) IT (Completed) PL (Completed) EE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019544-39 | Sponsor Protocol Number: 20090072 | Start Date*: 2010-10-04 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002918-43 | Sponsor Protocol Number: CNTO1275CRD3005 | Start Date*: 2017-02-28 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn’s Disease Patients Treated with Ustekinumab | |||||||||||||
Medical condition: Moderately to severely active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Ongoing) BE (Completed) DE (Completed) NL (Completed) FR (Completed) PT (Completed) SK (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010065-23 | Sponsor Protocol Number: P05553 | Start Date*: 2009-08-17 | ||||||||||||||||||||||||||
Sponsor Name:Essex Pharma GmbH | ||||||||||||||||||||||||||||
Full Title: Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05... | ||||||||||||||||||||||||||||
Medical condition: Active Moderate to Severe Ulcerative Colitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004381-24 | Sponsor Protocol Number: C87035 | Start Date*: 2015-03-02 | |||||||||||
Sponsor Name:UCB Celltech | |||||||||||||
Full Title: A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study) | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001653-32 | Sponsor Protocol Number: C0168IBD4020 | Start Date*: 2019-09-19 | |||||||||||
Sponsor Name:Janssen Scientific Affairs, LLC | |||||||||||||
Full Title: A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with inflammatory Bowel Disease | |||||||||||||
Medical condition: Inflammatory Bowel Diseases | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017998-37 | Sponsor Protocol Number: AGO/2009/015 | Start Date*: 2012-06-08 | |||||||||||||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||||||||||||
Full Title: Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFα-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy. | |||||||||||||||||||||||
Medical condition: Patients with an active spondyloarthropathy and with an active rheumatoid arthritis; who were diagnosed according to the classic ACR-criteria (American College of Rheumatology) for rheumatoid arthr... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003179-23 | Sponsor Protocol Number: GS-US-419-4015 | Start Date*: 2017-04-13 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD) | |||||||||||||
Medical condition: Small Bowel Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) HU (Completed) FR (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000609-38 | Sponsor Protocol Number: D5170C00002 | Start Date*: 2016-05-10 | |||||||||||
Sponsor Name:Allergan Limited | |||||||||||||
Full Title: A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or Are Intolerant t... | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BG (Completed) HU (Completed) BE (Completed) IT (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000381-20 | Sponsor Protocol Number: 27820 | Start Date*: 2007-11-16 | |||||||||||
Sponsor Name:Merck Serono S.A. - Geneva | |||||||||||||
Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001892-30 | Sponsor Protocol Number: GLPG1205-CL-201 | Start Date*: 2014-12-08 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate Crohn’s Dis... | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001733-16 | Sponsor Protocol Number: A3921083 | Start Date*: 2012-04-10 | |||||||||||
Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE C... | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Prematurely Ended) ES (Completed) HU (Completed) GR (Completed) AT (Completed) CZ (Completed) NL (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002942-19 | Sponsor Protocol Number: NT-2020 | Start Date*: 2021-03-16 |
Sponsor Name:Region Örebro län | ||
Full Title: NORDTREAT The Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile | ||
Medical condition: Crohn's disease and Ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) DK (Completed) IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005689-39 | Sponsor Protocol Number: A3921119 | Start Date*: 2013-06-27 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York 10017 | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) | |||||||||||||
Medical condition: Ankylosing Spondylitis (AS) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) NL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000634-21 | Sponsor Protocol Number: 64304500CRD2001 | Start Date*: 2016-11-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Cro... | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005151-83 | Sponsor Protocol Number: MUCUS | Start Date*: 2018-10-26 | |||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | |||||||||||||
Full Title: INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
